Eli Lilly and Company (NYSE:LLY) has been given a $73.00 target price by stock analysts at BMO Capital Markets in a research note issued to investors on Tuesday. The brokerage currently has a “sell” rating on the stock. BMO Capital Markets’ price objective points to a potential downside of 14.29% from the stock’s current price.

A number of other equities analysts also recently issued reports on LLY. Leerink Swann increased their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday. Piper Jaffray Companies reiterated a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a research note on Friday, October 13th. Barclays PLC increased their price objective on shares of Eli Lilly and from $90.00 to $98.00 and gave the company an “overweight” rating in a research note on Friday, October 13th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $84.23 to $88.00 in a research note on Tuesday, October 10th. Finally, Morgan Stanley set a $86.00 price objective on shares of Eli Lilly and and gave the company a “hold” rating in a research note on Friday, October 6th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Hold” and an average target price of $89.12.

Eli Lilly and (NYSE:LLY) traded down 2.31% during mid-day trading on Tuesday, reaching $85.17. The company’s stock had a trading volume of 8,696,010 shares. The stock has a market cap of $89.85 billion, a P/E ratio of 36.85 and a beta of 0.34. The firm’s 50 day moving average is $84.58 and its 200-day moving average is $82.25. Eli Lilly and has a one year low of $64.18 and a one year high of $89.09.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the company posted $0.88 earnings per share. Equities analysts expect that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/24/eli-lilly-and-company-lly-pt-set-at-73-00-by-bmo-capital-markets.html.

In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction on Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 990,000 shares of company stock valued at $82,949,650 over the last quarter. Insiders own 0.20% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Waldron LP raised its holdings in shares of Eli Lilly and by 46.7% during the first quarter. Waldron LP now owns 4,948 shares of the company’s stock worth $415,000 after purchasing an additional 1,574 shares during the last quarter. UBS Asset Management Americas Inc. raised its holdings in shares of Eli Lilly and by 7.5% during the first quarter. UBS Asset Management Americas Inc. now owns 6,888,963 shares of the company’s stock worth $579,431,000 after purchasing an additional 482,576 shares during the last quarter. TCI Wealth Advisors Inc. raised its holdings in shares of Eli Lilly and by 21.3% during the first quarter. TCI Wealth Advisors Inc. now owns 17,592 shares of the company’s stock worth $1,480,000 after purchasing an additional 3,086 shares during the last quarter. RNC Capital Management LLC raised its holdings in shares of Eli Lilly and by 46.8% during the first quarter. RNC Capital Management LLC now owns 424,733 shares of the company’s stock worth $35,724,000 after purchasing an additional 135,481 shares during the last quarter. Finally, Intrust Bank NA raised its holdings in shares of Eli Lilly and by 6.0% during the first quarter. Intrust Bank NA now owns 8,309 shares of the company’s stock worth $699,000 after purchasing an additional 472 shares during the last quarter. Institutional investors and hedge funds own 75.61% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.